August 1, 1989European Heart Journal
Monotherapy of stable angina with nicardipine hydrochloride: double-blind, placebo-controlled, randomized study
Key result
Nicardipine 40 mg increases exercise duration ~14% vs. placebo in stable angina.
- P<0.01
- n=46
Why the study?
Does nicardipine hydrochloride improve exercise duration and angina symptoms in patients with stable angina?
Population
46 patients with stable angina
Comparison
Nicardipine hydrochloride 30 or 40 mg three… vs Placebo three times a day
Design
RCT, randomized, repeated cross-over protocol, double-blind, placebo-controlled
Authors
Discussion
Loading...
Member takes
Implication
Supports nicardipine to prolong exercise duration in stable angina; extends CCB evidence while cautioning against beta-blocker withdrawal due to ischemic events.
Study Design
Type
RCT (n=46)
Blinding
Double-blind
Randomization
repeated cross-over
Structured PICO
Does nicardipine hydrochloride improve exercise duration and angina symptoms in patients with stable angina?
P
Population
46 patients with stable angina evaluated in a repeated cross-over protocol.
I
Intervention
Nicardipine hydrochloride 30 or 40 mg three times a day
C
Comparator
Placebo three times a day
O
Outcome
Mean exercise duration using a treadmill exercise protocolsurrogate
Main Result
Absolute Event Rate: 6.6% vs 5.8%
p-value: p=<0.01
Nicardipine monotherapy improves exercise duration in stable angina, but may precipitate unstable angina or myocardial infarction, particularly following beta-blocker withdrawal.
Cite This Study
Gheorghiade et al. (1989) conducted an RCT in stable angina (n=46). nicardipine hydrochloride vs. placebo was evaluated on mean exercise duration (40 mg dose) (p=<0.01). Nicardipine hydrochloride (40 mg) significantly increased mean exercise duration from 5.8 to 6.6 minutes (P<0.01) in patients with stable angina.